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to RN. This has also translated into a reduced risk of all cause 
mortality in large population series receiving PN as compared 
to RN, as a result of a lower rate of cardiovascular events 
potentially driven by CKD. Backed by these data, current 
guidelines (NCCN 2015, EAU 2014 and AUA 2009) make strong 
recommendations for PN in all T1a (up to 4 cm) and 
whenever feasible in T1b (4-7 cm) kidney cancers. The 
recommendation becomes imperative in patients with 
baseline CKD, bilateral tumours or tumour in a solitary 
kidney. Surprisingly, the only level I evidence available from 
a European RCT could not prove equivalence between PN and 
RN. While the trial did not meet accrual goals (541 out of 
1300 patients required), overall survival (the primary study 
end point) at 9.3 years of follow up was eventually better in 
the RN arm in spite of a better preserved renal function in 
the PN arm. Notably more cardiovascular events were 
observed in the PN group! All these observation taken 
together suggest that the survival advantage of PN over RN 
observed in large retrospective series or metanalyses is likely 
the effect of unaccountable selection biases in favour of PN 
(healthier patients more likely to be treated with PN). The 
beneficial effect of PN on kidney function is out of question, 
yet its clinical relevancy (= reduced risk of non cancer 
related morbidity) is restricted to patients with baseline CKD. 
Up to 30% of patients with SRM have some degree of baseline 
CKD and hence would require a PN that must be performed 
with surgical skill in order to optimize both oncological 
efficacy (negative surgical margin) and kidney function 
preservation (keep ischemia time < 25 minutes or even 
lower). The currently available surgical techniques (open, 
laparoscopic and robotic assisted) have all proved effective 
to accomplish a PN matching the criteria for both oncological 
and functional efficacy.  
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Renal-cellcarcinoma (RCC) is considered to be a 
radioresistant tumour, but this dogma iswrong and based on 
traditional radiation schedules. If given in a few (evensingle) 
fractions, but at a high fraction dose (stereotactic body 
radiotherapyor SBRT), RCC becomes highly radiosensitive. 
Both in the primary setting and intreatment of 
oligometastatic disease, local control rates >90% are 
achieved.There is an established biological rationale for the 
radiosensitivity ofrenal-cell carcinoma to SBRT which is based 
on the ceramide pathway, which isactivated only when a high 
dose per fraction is given. This pathway does notinvolve 
damage at the DNA level (nucleus) but at the level of the 
cellmembrane. The ultimate target of this pathway is the 
tumour vasculature,similar to lots of targeted drugs. 
Apartfrom the direct effect of SBRT on renal-cell carcinoma, 
stereotactic bodyradiotherapy can also induce an abscopal 
effect. This effect, caused byimmunological processes and 
involving dendritic cells, might be enhanced whentargeted 
drugs and stereotactic body radiotherapy are combined. 
Therefore,rigorous, prospective randomized trials involving a 
multidisciplinaryscientific panel are needed urgently. The 
presence of a radiation oncologist insuch panels is vital. 
Thisoral presentation will focus on: 
1. Radiobiologyof SBRT in RCC (ceramide pathway). 
2. Rationalefor the abscopal effect. 
3. Localcontrol rates of SBRT in RCC. 
4. Interactionbetween targeted drugs and SBRT. 
5. Increasingvisibility if radiation oncology in this setting. 
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There has been an increase in incidence of small renal masses 
over the last two decades. There is evidence that nephron 
sparing surgery offers equivalent long-term oncological 
results compared to radical nephrectomy. More recent 
evidence suggests that radical nephrectomy is associated 
with greater chronic renal insufficiency, which is in turn 
associated with increased risk of cardiovascular death, in 
patients with localised T1 renal mass. It is for these reasons 
that nephron sparing surgery is recommended, when 
technically feasible, for the management of renal tumour 
smaller than 7 cm.  
Partial nephrectomy is the gold standard treatment for small 
renal masses, however it is associated with a significant 
morbidity.  
Ablative treatments are alternative options that cause 
necrosis of the renal tumour without removing it. This can be 
achieved by heating tumour up to 80°C, with radiofrequency, 
or by freezing it below -40°C with cryosurgery. These 
percutaneous ablative treatments are performed under CT 
scan guidance or by laparoscopic approach. The percutaneous 
approach can be performed under local anaesthesia, which is 
particularly useful in fragile patients. These two minimally 
invasive ablative treatments allow, on average, to halve the 
postoperative morbidity when compared to partial 
nephrectomy. On the other hand, the risk of local recurrence 
is higher compared to partial nephrectomy. 
Cancer specific survival rate on literature review is quoted 
around 90 to 95% for T1a (<4 cm) tumours. The 5 years 
overall survival or metastatic free survival, don’t seem to be 
different from partial nephrectomy, if salvage treatments are 
proposed in case of local recurrence. To achieve these 
oncological results, appropriate patient selection along with 
adequate follow up is required.  
According to the various urological guidelines, renal biopsy 
must be performed prior to these ablative treatments. When 
a malignant tumour is confirmed histologically, these 
treatments are recommended for cortical tumours, smaller 
than 4 cm, ideally in elderly patients or patients with 
multiple comorbidities who have a reasonable life 
expectancy. Patients with bilateral synchronous tumours, 
genetic diseases leading to multiple bilateral recurrences, 
renal insufficiency or presence of solitary kidney, are also 
ideal candidates for ablative treatments. Patients with 
shorter life expectancy, tumours in the hilum or in close 
proximity to the collecting system and proximal ureter are 
contraindications. Cryosurgery appears to treat central 
tumours with less morbidity compared to radiofrequency 
ablation. Close radiological follow up is required. Renal CT 
scan or MRI is usually performed at regular intervals looking 
for any possible enhancement of recurrent/residual tumour.  
Conclusion: Partial nephrectomy remains the gold standard 
treatment for management of small renal tumours. Ablative 
treatment is a validated option associated with a favourable 
risk benefit balance, especially for fragile patients.  
 
Symposium: Modern techniques for old indications  
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The practice of brachytherapy nowadays has been developed 
decennia ago. In the course of years modifications are 
introduced by the use of different isotopes, the development 
of afterloading techniques, the introduction of image-guided 
techniques, and many more. Robotics technologies are on a 
wide scale increasingly being used in the treatment of 
patients. Also in brachytherapy this emerging technology has 
been adopted and is still in development. A robot is a 
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reprogrammable multifunctional manipulator designed to 
move materials, parts, tools, or specialized devices through 
variable programmed motions for the performance of a 
variety of tasks defined by The Robotics Institute of America. 
Dependent on the degree of automation and autonomy 
different classes can be recognized. Examples where robotic 
systems are used in brachytherapy are e.g. in prostate and 
bladder implantations. 
Several commercial and non-commercial systems exist to 
plan and place needles into the prostate. These systems can 
be automated for radioactive seed delivery and HDR 
treatments. Clinical study show robotic implantations to be 
feasible, although still manual corrections are done. 
In bladder brachytherapy a laparoscopic robotic system is 
available for catheter placement without the need to open 
the bladder (cystotomy). As with the traditional way of 
implanting, the catheters can be placed parallel and 
equidistantly. The major advantage is reduction of treatment 
morbidity with this technique, although also misplacements 
have been observed preventing adequate brachytherapy. 
Development of new technologies, such as robotic-aided 
brachytherapy implantations is welcomed to increase the 
precision and reproducibility of treatments and reduce 
morbidity. On the other side it should be appreciated that 
also for these techniques a learning curve exist. Clinical 
results in comparison to the traditional techniques should be 
awaited and carefully discussed before widespread 
adaptation of these new techniques. 
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Interventional radiotherapy (brachytherapy) was the first 
medical application in the treatment of cancer after 
discovering radium. User experience was growing over the 
time and useful rules of meaningful applicaton were 
developed. For many decades this experience based rules 
regulated the indication as well the performance of 
brachytherapy applications. After introducing milestone 
developments in the technical performance (stepping source 
technology and modern treatment planning software 
packages) as well in target definition modalities 
(multiparametric imaging, real-time imaging) and in quality 
assurance issues (medical & physical QA) biological planning 
and intensity modulation potential become available. 
Furthermore, interdisciplinary networking and education in 
the field lead to a higher level of cure rates with low toxicity 
and better Quality of Life of the patients. Economical 
comparison with other methods proved the necessity of 
involving interventional radiotherapy in to modern function 
preservative interdisciplinary treatments.  
Head & Neck cancer represents a special need for 
interdisciplinary cooperation because:  
1. Most of the recurrences following modern external beam 
radiotherapy (with or without complementary systemic 
treatment) are in-field recurrences. This indicates the need 
for higher local dose and interventional radiotherapy offers 
the highest possible dose in a small volume accompanied by 
very low radiation dose on surrounding normal tissues or 
organs at risk.  
2. Aggressive surgery cause functional or cosmetic demages 
on the head & neck. The combination of surgery and 
perioperative interventional radiotherapy results in higher 
rates of function preservation or in better cosmetic results.  
3. Modern multiparametric imaging techniques including 
hypoxia imaging has the potential to guide necessary very 
high dose areas to the right but very small volumes within the 
target.  
Regarding healthcare economy issues: preliminary analyses of 
healthcare professionals stated the advantage of involving 
interventional radiotherapy in to the treatment of head & 
neck cancers.  
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Vaginal cancer is a rare disease, accounting for only 2-3% of 
all gynaecological cancers. The majority (85%) of the tumours 
are squamous cell carcinomas and associated with a previous 
HPV infection.  
The FIGO classification is used for clinical staging and is an 
important prognostic factor. Approximately 25% of patients 
present with FIGO stage I, limited to the vaginal wall with a 
5-year survival rate of approximately 80%, compared to 20% 
for FIGO stage IV tumours that invade other pelvic organs or 
extend beyond the true pelvis (10-15% of patients). Other 
known prognostic factors are site, size and histologic 
subtype.  
The treatment of vaginal cancer may include surgery in 
limited stage I disease, in the upper third of the vagina. 
However, surgery is often extensive especially if tumors 
extend to the lower two thirds of the vagina and it is often 
difficult to achieve negative margins in tumors larger than 2-
3 cm. Because of these difficulties, radiotherapy is generally 
recommended as the standard treatment for all vaginal 
cancers irrespectively of the stage.  
In general, radiotherapy is very similar to that for cervical 
cancer and includes a combination of 45-50 Gy external beam 
radiotherapy (EBRT) with concomitant weekly cisplatinum 
followed by brachytherapy boost to a total dose of 70 Gy to 
80 Gy. With regard to the brachytherapy technique small 
residual tumors (≤5mm thick) can be treated with 
intracavitary technique alone while combined intracavitary 
and interstitial technique should be considered for larger 
tumours.  
Published data on the results of radiotherapy are mainly 
based on small retrospective studies and can be categorised 
in two groups. The first group includes studies where patients 
mainly were treated with 2-dimensional (x-ray based) 
radiotherapy. The second small group includes studies where 
patients have been treated using image guided (CT or MRI) 
adaptive treatment planning. Any direct comparison between 
the two groups of studies is difficult because of the 
retrospective nature of the data, limited number of patients 
and short follow-up. However, it seems that image guided 
brachytherapy is associated an increased local control rate 
from 75% (44-87%) for the radiograph based studies to 85% 
(75-94%) for the studies using an image guided approach, 
together with a decrease in moderate to severe treatment 
related morbidity. In 2005 the GEC-ESTRO GYN group 
successfully introduced an image guided adaptive target 
concept for brachytherapy in locally advanced cervical 
cancer. This concept takes the initial tumour extent at time 
of diagnosis as well as tumour regression during EBRT into 
account. Several studies have shown a therapeutic benefit 
with improvements in local control and reductions in 
moderate to severe morbidity using this concept.  
Based on these results, a task group within GEC ESTRO GYN 
was formed with the aim to introduce image guided adaptive 
target concept in the treatment of vaginal cancer. This 
initiative started in the beginning of 2014 comparing the 
different target concepts from each of the 5 involved 
centres. In a next step each centre contoured 5 different 
cases with their own target concept in mind. During this work 
many similarities were found in the target concepts and 
between the contours of each centre. Therefore the group 
proceeded to investigate the differences and similarities in 
dose and treatment planning. In this project each centre 
performed treatment planning for the 5 contoured cases 
using both their own target contours and on a set of contours 
that were provided.  
Importantly, radiotherapy for vaginal cancer is based on a 
combination of clinical findings as well as imaging. Especially 
for the clinical findings the precise documentation can be 
challenging. In order to increase the uniform reporting a 
clinical drawing for this documentation has been developed. 
